Skip to main content
NeoImmuneTech, Inc. logo

NeoImmuneTech, Inc. — Investor Relations & Filings

Ticker · 950220 ISIN · KR8840140006 LEI · 254900489QR747TPTT13 KO Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2026-03-19 Audit Report / Informat…
Country US United States of America
Listing KO 950220

About NeoImmuneTech, Inc.

https://www.neoimmunetech.com/en

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from NeoImmuneTech. It provides key financial data, audit opinions, and financial statements for the fiscal year. While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a simple announcement of report availability (RPA). In the context of Korean regulatory filings (DART/KIND), this specific format is classified as an Audit Report/Information document. FY 2025
2026-03-19 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for NeoImmuneTech, Inc. for the fiscal year 2025 (Jan 1, 2025 - Dec 31, 2025). It contains comprehensive sections including company overview, management history, capital structure, business operations, and detailed financial/operational disclosures. This structure corresponds to the standard Korean Annual Report (10-K equivalent). FY 2025
2026-03-19 Korean
[기재정정]주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for NeoImmuneTech. It details the meeting date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and includes a correction notice for a previous filing. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon.
2026-03-13 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for NeoImmuneTech, Inc. It includes the agenda for the meeting, details on director and auditor appointments, and management's reference materials including financial statements (balance sheets, income statements, etc.) for the fiscal year 2025. While it contains financial data, it is primarily a proxy statement/notice for a shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2026-03-13 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for NeoImmuneTech. It details the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and provides biographical details for board nominees. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting agendas and to request their votes.
2026-03-10 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted by NeoImmuneTech to report the reason for holding their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). This is a specific regulatory disclosure requirement in the Korean market regarding shareholder meeting scheduling. Since it does not contain the actual proxy materials, voting results, or the meeting presentation itself, but rather a regulatory notification regarding the scheduling, it falls under the general regulatory filing category.
2026-03-10 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.